Distribution of Bexsero® antigen sequence types (BASTs) in invasive meningococcal disease isolates: implications for immunisation
Serogroup B is the only major disease-associated capsular group of Neisseria meningitidis for which no protein-polysaccharide conjugate vaccine is available. This has led to the development of multi-component protein-based vaccines that target serogroup B invasive meningococcal disease (IMD), inclu...
Egile Nagusiak: | Brehony, C, Rodrigues, C, Borrow, R, Smith, A, Cunney, R, Moxon, E, Martin C.J., M |
---|---|
Formatua: | Journal article |
Argitaratua: |
Elsevier
2016
|
Antzeko izenburuak
-
Genomic surveillance and meningococcal group B vaccine coverage estimates after introduction of the vaccine into the national immunisation programme in the UK
nork: Rodrigues, C, et al.
Argitaratua: (2017) -
Health and economic outcomes of introducing the new MenB vaccine (Bexsero) into the Italian routine infant immunisation programme.
nork: Marcello Tirani, et al.
Argitaratua: (2015-01-01) -
Meningococcal meningitis presenting postinfant group B meningococcal immunisation
nork: So, N, et al.
Argitaratua: (2018) -
Progressive decrease in the potential usefulness of meningococcal serogroup B vaccine (4CMenB, Bexsero®) in Gipuzkoa, Northern Spain.
nork: Emilio Pérez-Trallero, et al.
Argitaratua: (2014-01-01) -
Need for Optimisation of Immunisation Strategies Targeting Invasive Meningococcal Disease in the Netherlands
nork: Josefien Cornelie Minthe Bousema, et al.
Argitaratua: (2015-11-01)